Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
SynopsisC

When should I stop anticoagulation for atrial fibrillation?

Michelle Greiver
CMAJ May 24, 2005 172 (11) 1437; DOI: https://doi.org/10.1503/cmaj.1041026
Michelle Greiver
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2005 CMA Media Inc. or its licensors

I am a practising community family physician with 199 patients over the age of 64 years. Eleven (5.5%) of them are taking warfarin for atrial fibrillation. Anticoagulation reduces the relative risk of stroke by about 70% over 5 years;1 however, patients are at risk of bleeding. Although the risk of a serious life-threatening or fatal bleed is about 5% over 5 years for most patients, it is 17% over 5 years for patients over the age of 80.2

Six of my patients using warfarin for atrial fibrillation are over the age of 80. I calculated their 5-year risk of having a stroke (using the Framingham calculator, www.statcoder.com) to be 18%, 19%, 21%, 31%, 41% and 55% respectively. I determined that, if a patient has a risk of stroke of 24% over 5 years, then that risk would fall by 70% with warfarin, to 7.2%. The net improvement or absolute risk reduction would be 16.8%. If the risk of a serious bleed from warfarin therapy is 17% over 5 years, then all patients with a stroke risk of 24% or less would have the benefit of warfarin therapy counterbalanced by a risk of a serious side effect. (Note that by using general principles of risk equivalence,3 this determination can also be calculated as risk of adverse event ÷ relative risk benefit — in this case 17% ÷ 0.7 = 24%.) I reviewed the treatment of my 6 patients, and it appeared to me that 3 of them should continue to take warfarin and 3 should consider switching to ASA.

I acknowledge limitations to my approach. The estimates of risk of anticoagulation are limited, since they are derived from a single trial (and not a meta-analysis of trials in several populations) and have wide confidence intervals surrounding them. In addition, risks (of the condition and the treatment) are patient specific and depend on factors not included in the calculations (e.g., concurrent illnesses and medication use, and whether the patient agrees with my assumption that a serious outcome such as stroke might have the same impact on one's life as a severe bleed). Still, I wonder: Is my approach to risk equivalence ready for prime time?

Footnotes

  • What's your opinion?

    We invite you to submit your ideas about the author's approach to risk equivalence by sending an eLetter response to this article at www.cmaj.ca. The best comments will be summarized in an upcoming issue and a small prize awarded.

    Do you have a case that you can't diagnose? Send a description of it to the attention of Dr. Wooltorton at eric.wooltorton{at}cma.ca.

References

  1. 1.↵
    Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Cochrane Database Syst Rev 2001;(1):CD001938.
  2. 2.↵
    Fihn SD, Callahan CM, Martin DC, McDonnell MB, Henikoff JG, White RH, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996;124:970-9.
    OpenUrlPubMed
  3. 3.↵
    Barratt A, Wyer PC, Hatala R, McGinn T, Dans AT, Keitz S, et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171(4): 353-8.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 172 (11)
CMAJ
Vol. 172, Issue 11
24 May 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
When should I stop anticoagulation for atrial fibrillation?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
When should I stop anticoagulation for atrial fibrillation?
Michelle Greiver
CMAJ May 2005, 172 (11) 1437; DOI: 10.1503/cmaj.1041026

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
When should I stop anticoagulation for atrial fibrillation?
Michelle Greiver
CMAJ May 2005, 172 (11) 1437; DOI: 10.1503/cmaj.1041026
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Cardiology: arrhythmias
    • Drugs: cardiovascular system

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire